Improvement of oral drug treatment by temporary inhibition of drug transporters and/or cytochrome P450 in the gastrointestinal tract and liver: An overview

Oncologist

Volumn 7, Issue 6, 2002, Pages 516-530

  Kruijtzer, C M F ^a   Beijnen, J H ^b,c   Schellens, J H M ^a,b,c  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b SLOTERVAART HOSPITAL   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Cytochrome P450; Drug transporters; Oral chemotherapy; Pharmacokinetics

Indexed keywords

BIRICODAR; CYCLOSPORIN A; CYTOCHROME P450; CYTOTOXIC AGENT; DOCETAXEL; ELACRIDAR; IRINOTECAN; KETOCONAZOLE; MULTIDRUG RESISTANCE PROTEIN; PACLITAXEL; QUINIDINE; RITONAVIR; TOPOTECAN; VALSPODAR; VERAPAMIL; ZOSUQUIDAR;

AREA UNDER THE CURVE; ARTICLE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG INHIBITION; DRUG RECEPTOR BINDING; DRUG TRANSPORT; GASTROINTESTINAL TRACT; LIVER; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL AVAILABILITY; CYTOCHROME P-450 ENZYME SYSTEM; HIV INFECTIONS; HIV-1; HUMANS; INTESTINAL ABSORPTION; INTESTINAL MUCOSA; LIVER; NEOPLASM PROTEINS; P-GLYCOPROTEINS; PROTEASE INHIBITORS;

EID: 0036909078     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.7-6-516     Document Type: Article

References (172)

1. Demario MD, Ratain MJ. Oral chemotherapy: Rationale and future directions. J Clin Oncol 1998;16:2557-2567.
2. Liu G, Franssen E, Fitch MI et al. Patient preferences for oral versus intravenous palliative therapy. J Clin Oncol 1997;15:110-115.
3. Meerum Terwogt JM, Beijnen JH, ten Bokkel Huinink WW et al. Co-administration of cyclosporin A enables oral therapy with paclitaxel. Lancet 1998;352:285.
4. Sparreboom A, van Asperen J, Mayer U et al. Limited oral bioavailability and active epithelial excretion of paclitaxel caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA 1997;94:2031-2035.
5. Kuhn J, Rizzo J, Eckhardt J et al. Phase I bioavailability study of oral topotecan. Proc Am Soc Clin Oncol 1995;14:474.
6. Schellens JHM, Creemers GJ, Beijnen JH et al. Bioavailability and pharmacokinetics of oral topotecan: A new topoisomerase inhibitor. Br J Cancer 1996;73:1268-1271.
7. Hellriegel ET, Bjornnson TD, Hauck WW. Interpatient variability in bioavailability is related to the extent of absorption: Implications for bioavailability and bioequivalence studies. Clin Pharmacol Ther 1996;60:601-607.
8. Huizing MT, Giaccone G, van Warmerdam LJC et al. Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and sequencing study in patients with non-small cell lung cancer. J Clin Oncol 1997;15:317-329.
9. Van Asperen J, van Tellingen O, Beijnen JH et al. The pharmacological role of P-glycoprotein in the intestinal epithelium. Pharmacol Res 1998;37:429-435.
10. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976;455:152-162.
11. Chen CJ, Chin JE, Ueda K et al. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug resistant human cells. Cell 1986;47:381-389.
12. Gros P, Croop J, Housman D. Mammalian multidrug resistance gene: Complete cDNA sequence indicates strong homology to bacterial transport proteins. Cell 1986;47:371-380.
13. Hsu SH, Lothstein L, Horwitz SB. Differential overexpression of three mdr gene family members in multi-drug resistant J774.2 mouse cells. Evidence that distinct P-glycoprotein precursors are encoded by unique mdr genes. J Biol Chem 1989;264:12053-12062.
14. Ling V. Multidrug resistance: Molecular mechanisms and clinical relevance. Cancer Chemother Pharmacol 1997;40(suppl):S3-S8.
15. Bradshaw DM, Arceci RJ. Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance. J Clin Oncol 1998;16:3674-3690.
16. Leighton Jr JC, Goldstein L. P-glycoprotein in adult solid tumors. Expression and prognostic significance. Hematol Oncol Clin North Am 1995;9:251-273.
17. Croop JM, Raymond M, Haber D et al. The three mouse multidrug resistance (mdr) genes are expressed in a tissue specific manner in normal mouse tissues. Mol Cell Biol 1989;9:1346-1350.
18. Devault A, Gros P. Two members of the mouse mdr gene family confer multidrug resistance with overlapping but distinct drug specificities. Mol Cell Biol 1990;10:1652-1663.
19. Schinkel AH, Smit JJM, van Tellingen O et al. Disruption of the mouse mdr a P-glycoprotein gene leads to a deficiency in the blood brain barrier and to increased sensitivity to drugs. Cell 1994;77:491-502.
20. Gros P, Ben Neriah YB, Croop JM et al. Isolation and expression of a complementary DNA that confers multidrug resistance. Nature 1986;323:728-731.
21. Scotto KW, Biedler JL, Melera PW. Amplification and expression of genes associated with multidrug resistance in mammalian cells. Science 1986;232:751-755.
22. Thiebaut F, Tsuruo T, Hamada H et al. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987;84:7735-7738.
23. Fojo AT, Ueda K, Slamon DJ et al. Expression of a multidrug resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 1987;84:265-269.
24. Van Asperen J, Mayer U, van Tellingen O et al. The pharmacological role of P-glycoprotein in the blood-brain barrier. J Pharm Sci 1997;86:881-884.
25. Borst P, Schinkel AH. What we have learnt thus far from mice with disrupted P-glycoprotein genes. Eur J Cancer 1996;32A:985-990.
26. Schinkel AH, Mayer U, Wagenaar E et al. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug transporting) P-glycoproteins. Proc Natl Acad Sci USA 1997;94:4028-4033.
27. Goldstein LJ, Galski H, Fojo A et al. Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 1989;81:116-124.
28. Tsuruo T, Iida H, Tsukagoshi S et al. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 1981;41:1967-1972.
29. Ford JM, Hait WN. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 1990;42:155-199.
30. Slater LM, Sweet P, Stupecky M et al. Cyclosporin A reverses vincristine and daunorubicin resistance in acute lymphatic leukemia in vitro. J Clin Invest 1986;77:1405-1408.
31. Hyafil F, Vergely C, Du Vignaud P et al. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res 1993;53:4595-4602.
32. Van Zuylen L, Sparreboom A, Van der Gaast A et al. The orally administered P-glycoprotein inhibitor R101933 does not alter the plasma pharmacokinetics of docetaxel. Clin Cancer Res 2000;6:1365-1371.
33. Dantzig AH, Shepard RL, Cao J et al. Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res 1996;56:4171-4179.
34. Rogan AM, Hamilton TC, Young RC et al. Reversal of adriamycin resistance by verapamil in human ovarian cancer. Science 1984;224:994-996.
35. Relling MV. Are the major effects of P-glycoprotein modulators due to altered pharmacokinetics of anticancer drugs? Ther Drug Monit 1996;18:350-356.
36. Lum BL, Fisher GA, Brophy NA et al. Clinical trials of modulation of multidrug resistance: pharmacokinetic and Pharmacodynamic considerations. Cancer 1993;72(suppl 11):3502-3514.
37. Dalton WS, Crowley JJ, Salmon SS et al. A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma: A Southwest Oncology Group Study. Cancer 1995;75:815-820.
38. Milroy R. A randomised clinical study of verapamil in addition to combination chemotherapy in small cell lung cancer. West of Scotland Lung Cancer research Group and the Aberdeen Oncology Group. Br J Cancer 1993;68:813-818.
39. Wishart GC, Bissett D, Paul J et al. Quinidine as a resistance modulator of epirubicin in advanced breast cancer: Mature results of a placebo controlled randomized trial. J Clin Oncol 1994;12:1771-1777.
40. Boote DJ, Dennis IF, Twentyman PR et al. Phase I study of etoposide with SDZ PSC 833 as a modulator of multi drug resistance in patients with cancer. J Clin Oncol 1996;14:610-618.
41. Rowinsky EK, Smith L, Wang YM et al. Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP. J Clin Oncol 1998; 16:2964-2976.
42. Wacher VJ, Wu CY, Benet LZ. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: Implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 1995;13:129-134.
43. Watkins PB. The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Adv Drug Deliv Rev 1997;27:161-170.
44. Wacher VJ, Silverman JA, Zhang Y et al. Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J Pharm Sci 1998;87:1322-1330.
45. Cummins CL, Jacobsen W, Benet LZ. Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. J Pharmacol Exp Ther 2002;300:1036-1045.
46. Cole SPC, Bhardwaj G, Gerlach JH et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992;258:1650-1654.
47. Borst P, Evers R, Kool M et al. A family of drug transporters: The multidrug resistance-associated proteins. J Natl Cancer Inst 2000;92:1295-1302.
48. Borst P, Elferink RO. Mammalian ABC transporters in helath and disease. Annu Rev Biochem 2002;71:537-592.
49. Evers R, Zaman GJ, van Deemter L et al. Basolateral localization and export activity of the human multi-drug resistance-associated protein in polarized pig kidney cells. J Clin Invest 1996;97:1211-1218.
50. Hipfner DR, Deeley RG, Cole SP. Structural, mechanistic and clinical aspects of MRP 1. Biochim Biophys Acta 1999;1461:359-376.
51. Wijnholds J, Evers R, van Leusden MR et al. Increased sensitivity to anticancer drugs and decreased inflammatory response in mice lacking the multi drug resistance-associated protein. Nat Med 1997;3:1275-1279.
52. Lorico A, Rappa G, Finch RA et al. Disruption of the murine MRP (multi drug resistance protein) gene leads to increased sensitivity to etoposide and increased levels of gluthathione. Cancer Res 1997;57:5238-5242.
53. Rappa G, Finch RA, Sartorelli AC et al. New insights into the biology and pharmacology of the multi drug resistance protein (MRP) from gene knockout models. Biochem Pharmacol 1999;58:557-562.
54. Ishikawa T. The ATP-dependent glutathione S-conjugate export pump. Trends Biochem Sci 1992;17:463-468.
55. Zaman GJR, Lankelma J, van Tellingen O et al. Role of glutathione in the export of compounds from cells by the multidrug-resistance-associated protein. Proc Natl Acad Sci USA 1995;92:7690-7694.
56. Hooijberg JH, Broxterman HJ, Kool M. Antifolate resistance mediated by the multi drug resistance proteins MRP1 and MRP2. Cancer Res 1999;59:2532-2535.
57. Henderson GB, Hughes TR, Saxena M. Functional implications from the effects of 1-chloro-2,4-dinitrobenzene and ethacrynic acid on efflux routes for methotrexate and cholate in L1210 cells. J Biol Chem 1994;269:13382-13389.
58. Wijnholds J, Scheffer GL, van der Valk M et al. Multidrug resistance protein 1 protects the oropharyngeal mucosal layer and the testicular tubules against drug-induced damage. J Exp Med 1998;188:797-808.
59. Wijnholds J, de Lange EC, Scheffer GL et al. Multidrug resistance protein I protects the choroid plexus epithelium and contributes to the blood-cerebrospinal fluid barrier. J Clin Invest 2000;105:279-285.
60. König J, Nies AT, Cui Y et al. Conjugate export pumps of the multidrug resistance protein (family): Localization, substrate specificity, and MRP-2 mediated drug resistance. Biochim Biophys Acta 1999;1461:377-394.
61. Kartenbeck J, Leuschner U, Mayer R et al. Absence of the canalicular isoform of the MRP gene-encoded conjugate export pump from the hepatocytes in Dubin-Johnson syndrome. Hepatology 1996;23:1061-1066.
62. Paulusma CC,Kool M,Bosma PJ et al. A mutation in the human canalicular multispecific organic anion transporter gene causes the Dubin-Johnson syndrome. Hepatology 1997;25:1539-1542.
63. Gutmann H, Fricker G, Drewe J et al. Interactions of HIV protease inhibitors with ATP-dependent drug export proteins. Mol Pharmacol 1999;56:383-389.
64. Chu XY, Kato Y, Sugiyama Y. Multiplicity of biliary excretion mechanisms for irinotecan, CPT-11 and its metabolites in rats. Cancer Res 1997;57:1934-1938.
65. Cui Y, Konig J, Buchholz JK et al. Drug resistance and ATP dependent conjugate transport mediated by the apical multi drug resistance protein, MRP2, permanently expressed in human and canine cells. Mol Pharmacol 1999;55:929-937.
66. Cole SP, Sparks KE, Fraser K et al. Pharmacological characterization of multi drug resistant MRP-transfected human tumor cells. Cancer Res 1994;54:5902-5910.
67. Ishikawa T, Wright CD, Ishizuka H. GS-X pump is functionally overexpressed in cis-diamminedichloroplatinum (II)-resistant human leukemia HL-60 cells and down-regulated by cell differentiation. J Biol Chem 1994;269:29085-29093.
68. König J, Rost D, Cui Y et al. Characterization of the human multidrug resistance protein isoform MRP3 localized to the basolateral hepatocyte membrane. Hepatology 1999;29:1156-1163.
69. Schuetz JD, Connelly MC, Sun D et al. MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nat Med 1999;5:1048-1051.
70. Wijnholds J, Mol CA, van Deemter L et al. Multidrug resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. Proc Natl Acad Sci USA 2000;97:7476-7481.
71. Kool M, van der Linden M, de Haas M et al. Expression of human MRP6, a homologue of the multidrug resistance protein gene MRP1, in tissues and cancer cells. Cancer Res 1999;59:175-182.
72. Doyle LA, Yang W, Abruzzo LV et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 1998;95:15665-15670.
73. Miyake K, Mickley L, Litman T et al. Molecular cloning of CDNAs which are highly overexpressed in mitoxantrone-resistant cells: Demonstration of homology to ABC transport genes. Cancer Res 1999;59:8-13.
74. Allikmets R, Schriml LM, Hutchinson A et al. A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4Q 22 that is involved in multi drug resistance. Cancer Res 1998;58:5337-5339.
75. Jonker JW, Smit JW, Brinkhuis RF et al. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J Natl Cancer Inst 2000;92:1651-1656.
76. Maliepaard M, Scheffer GL, Faneyte IF et al. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 2001;8:3458-3464.
77. Zhou S, Schuetz JD, Bunting KD. The ABC transporter Bcrpl/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 2001;7:1028-1034.
78. Maliepaard M, van Gastelen MA, de Jong LA et al. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res 1999;59:4559-4563.
79. Allen JD, Brinkhuis RF, Wijnholds J et al. The mouse Bcrp/Mxr/Abcp gene: Amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone or doxorubicin. Cancer Res 1999;59:4237-4241.
80. Den Ouden D, Van den Heuvel M, Schoester M et al. In vitro effect of GF120918, a novel reversal agent of multidrug resistance on acute leukemia and multiple myeloma cells. Leukemia 1996;10:1930-1936.
81. De Bruin M, Miyake K, Litman K et al. Reversal of resistance by GF120918 in cell lines expressing the half transporter, MXR. Cancer Lett 1999;146:117-126.
82. Maliepaard M, van Gastelen MA, Tohgo A et al. Circumvention of BCRP-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918. Clin Cancer Res 2001;7:935-941.
83. Erlichman C, Boerner SA, Hallgren CG et al. The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux. Cancer Res 2001;61:739-748.
84. Nelson DR, Kamataki T, Waxman DJ et al. The P450 superfamily: Update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA Cell Biol 1993;12:1-51.
85. Guengerich FP. In vitro techniques for studying drug metabolism. J Pharmacokinet Biopharm 1998;24:521-533.
86. Lin JH, Lu AY. Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet 1998;35:361-390.
87. Watkins PB, Wrighton SA, Schuetz EG et al. Identification of glucocorticoid-inducible cytochromes P450 in the intestinal mucosa of rats and man. J Clin Invest 1987;80:1029-1036.
88. Lown KS, Kolars JC, Thummel KE. Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test. Drug Metab Dispos 1994;22:947-955.
89. Kolars JC, Schmiedlin-Ren P, Schuetz JD et al. Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest 1992;90:1871-1878.
90. Kolars JC, Awni WM, Merion RM et al. First-pass metabolism of cyclosporin A by the gut. Lancet 1991;338:1488-1490.
91. Paine MF, Khalighi M, Fisher JM et al. Characterization of interintestinal and intraintestinal variations in human CYP3A- dependent metabolism. J Pharmacol Exp Ther 1997;283:1552-1562.
92. Wrighton SA, Ring BJ, Watkins PB. Identification of a polymorphically expressed member of the human cytochrome P450-III family. Mol Pharmacol 1989;36:97-105.
93. Kolars JC, Lown KS, Schmiedlin-Ren P et al. CYP3A expression in human gut epithelium. Pharmacogenetics 1994;4:247-259.
94. Kivistö KT, Bookjans G, Fromm MF et al. Expression of CYP3A4 and CYP3A5 and CYP3A7 in human duodenal tissue. Br J Clin Pharmacol 1996;42:387-389.
95. Watkins PB, Wrighton SA, Maurel P et al. Identification of an inducible form of cytochrome P450 in human liver. Proc Natl Acad Sci USA 1985;82:6310-6314.
96. Huizing MT, Misser VH, Pieters RC et al. Taxanes: A new class of antitumor agents. Cancer Invest 1995;13:381-404.
97. Fujita H, Okamoto M, Takao A et al. Pharmacokinetics of paclitaxel in experimental animals. Part 1. Blood levels. Gan To Kagaku Ryoho 1994;21:653-658.
98. Eiseman JL, Eddington ND, Leslie J et al. Plasma pharmacokinetics and tissue distribution of paclitaxel in CD2F1 mice. Cancer Chemother Phamacol 1994;34:465-471.
99. Rowinsky EK, Wright M, Monsarrat B et al. Clinical pharmacology and metabolism of taxol (paclitaxel): Update 1993. Ann Oncol 1994;5(suppl 6):S7-S16.
100. Sonnichsen DS, Liu Q, Schuetz EG et al. Variability in human cytochrome P450 paclitaxel metabolism. J Pharmacol Exp Ther 1995;275:566-575.
101. Walle T, Walle K, Kumar GN et al. Taxol metabolism and disposition in cancer patients. Drug Metabol Dispos 1995;23:506-512.
102. Sparreboom A, van Tellingen O, Nooijen WJ et al. Preclinical pharmacokinetics of paclitaxel and docetaxel. Anticancer Drugs 1998;1:1-17.
103. van Asperen J, van Tellingen O, Sparreboom A et al. Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833. Br J Cancer 1997;76:1181-1183.
104. Van Asperen J, van Tellingen O, van der Valk MA et al. Enhanced oral absorption and decreased elimination of paclitaxel in mice with cyclosporin A. Clin Cancer Res 1998;4:2293-2297.
105. Harris JW, Rahman A, Kim BR et al. Metabolism of taxol by human hepatic microsomes and liver slices: Participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res 1994;54:4026-4035.
106. Cresteil T, Monsarrat B, Alvinerie P et al. Taxol metabolism by human liver microsomes: Identification of cytochrome P450 isozymes involved in its biotransformation. Cancer Res 1994;54:386-392.
107. Webber IR, Peters WH, Back DJ. Cyclosporin metabolism by human gastrointestinal mucosal microsomes. Br J Clin Pharmacol 1992;33:661-664.
108. Bardelmeijer HA, Beijnen JH, Brouwer KR et al. Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein. Clin Cancer Res 2000;6:4416-4421.
109. Wils P, Phung-Ba V, Warnery A et al. Polarized transport of docetaxel and vinblastine mediated by P-glycoprotein in human intestinal epithelial cell monolayers. Biochem Parmacol 1994;48:1528-1530.
110. Shirakawa K, Takar K, Tanigawara Y et al. Interaction of docetaxel (Taxotere) with human P-glycoprotein. Jpn J Cancer Res 1999;90:1380-1386.
111. Bardelmeijer HA, Ouwehand M, Buckle T et al. Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir. Proc Am Assoc Cancer Res 2002;43:262.
112. Marre F, Sanderink GJ, Desousa G et al. Hepatic biotransformation of docetaxel (taxotere) in vitro: Involvement of the CYP3A subfamily in humans. Cancer Res 1996;56:1296-1302.
113. Meerum Terwogt JM, Malingré MM, Beijnen JH et al. Coadministration of cyclosporin enables oral therapy with paclitaxel. Clin Cancer Res 1999;5:3379-3384.
114. Malingré MM, Terwogt JM, Beijnen JH et al. A phase I and pharmacokinetic study of oral paclitaxel. J Clin Oncol 2000;18:2468-2475.
115. Malingré MM, Schellens JHM, van Tellingen O et al. Metabolism and excretion of paclitaxel after oral administration in combination with cyclosporin A and after intravenous adminisration. Anticancer Drugs 2000;11:813-820.
116. Gianni L, Kearns CM, Giani A et al. Nonlinear pharmacokinetics and metabolism of paclitaxel and its phamacokinetic/ pharmacodynamic relationship in humans. J Clin Oncol 1995;13:180-190.
117. Sparreboom A, van Tellingen O, Nooijen WJ et al. Tissue distribution, metabolism and excretion of paclitaxel in mice. Anticancer Drugs 1996;7:78-86.
118. van Tellingen O, Huizing MT, Panday VR et al. Cremophor EL causes (pseudo) nonlinear pharmacokinetics of paclitaxel in patients. Br J Cancer 1999;81:330-335.
119. Malingré MM, Beijnen JH, Rosing H et al. A phase I and pharmacokinetic study of bidaily dosing of oral paclitaxel in combination with cyclosporin A. Cancer Chemother Pharmacol 2001;47:347-354.
120. Malingré MM, Beijnen JH, Rosing H et al. The effect of different doses of cyclosporin A on the systemic exposure of orally administered paclitaxel. Anticancer Drugs 2001;12:351-358.
121. Malingré MM, Beijnen JH, Rosing H et al. Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients. Br J Cancer 2001;84:42-47.
122. Kruijtzer CMF, Schellens JHM, Mezger J et al. A phase II and pharmacological study of weekly oral paclitaxel (Paxoral®) plus cyclosporin A (CsA) in patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol (in press).
123. Wozniak AJ. Single agent vinorelbine in the treatment of non-small cell lung cancer. Semin Oncol 1999;26(suppl 16):62-66.
124. Ten Bokkel Huinink WW, Bergman B, Chemaissaini A et al. Single-agent gemcitabine: An active and better tolerated alternative to standard cisplatin-based therapy in locally advanced or metastatic non-small cell lung cancer. Lung Cancer 1999;26:85-94.
125. Socinski MA. Single-agent paclitaxel in the treatment of advanced non-small cell lung cancer. The Oncologist 1999;4:408-416.
126. Miller V, Kris M. Docetaxel (Taxotere) as a single agent and in combination chemotherapy for the treatment of patients with advanced non-small cell lung cancer. Semin Oncol 2000;27(suppl 3):3-10.
127. Ranson M, Davidson N, Nicolson M et al. Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small cell lung cancer. J Natl Cancer Inst 2000;92:1074-1080.
128. Gatzemeier U, Heckmayr M, Neuhauss R et al. Phase II study with paclitaxel for the treatment of advanced inoperable non-small cell lung cancer. Lung Cancer 1995;12(suppl 2):S101-S106.
129. Cullinan SA, Moertel CG, Wieand HS et al. Controlled evaluation of three drug combination regimens versus fluorouracil alone for the therapy of advanced gastric cancer. J Clin Oncol 1994;12:412-416.
130. Wils JA, Klein HO, Wagener DJ et al. Sequential high-dose methotrexate and fluorouracil combined with doxorubicin. A step ahead in the treatment of advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol 1991;9:827-831.
131. Webb A, Cunningham D, Scarffe H et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997;15:261-267.
132. Boot H, Cats A, Tonino S et al. Epirubicin, cisplatin and continuous 5-FU chemotherapy (ECF-regimen) in patients with cancer of the gastroesophageal junction and stomach. Gastroenterology 2002;122(suppl):A601.
133. Ohtsu A, Boku N, Tamura F et al. An early phase II study of a 3-hour infusion of paclitaxel for advanced gastric cancer. Am J Clin Oncol 1998;21:416-419.
134. Cascinu S, Graziano F, Cardarelli N et al. Phase II study of paclitaxel in pretreated advanced gastric cancer. Anticancer Drugs 1998;9:307-310.
135. Einzig AL, Lipsitz S, Wiernik PH et al. Phase II trial of Taxol in patients with adenocarcinoma of upper gastrointestinal tract (UGIT). The Eastern Cooperative Oncology Group (ECOG) results. Invest New Drugs 1995;3:223-227.
136. Huizing MT, Keung AC, Rosing H et al. Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum pretreated ovarian cancer patients. J Clin Oncol 1993;11:2127-2135.
137. Malingré MM, Richel DJ, Beijnen JH et al. Coadministration of cyclosporin A strongly enhances the oral bioavailability of docetaxel. J Clin Oncol 2001;19:1160-1166.
138. Burstein HJ, Manola J, Younger J et al. Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol 2000;18:1212-1219.
139. Kruijtzer CMF, Malingré MM, Schornagel JH et al. A phase II study with weekly oral docetaxel and cyclosporin A in patients with metastatic breast cancer. Proc Am Soc Clin Oncol 2001;20:1941.
140. Lück HJ, Donnè S, Glaubitz M et al. Phase I study of weekly docetaxel (Taxotere®) in heavily pretreated breast cancer patients. Eur J Cancer 1997;33(suppl):158.
141. Hainsworth JD, Burris 3rd HA, Yardley DA et al. Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: A Minnie Pearl Cancer Research Network Phase II trial. J Clin Oncol 2001;19:3500-3505.
142. Bruno R, Hille D, Riva A et al. Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 1998;16:187-196.
143. Rosing H, Lustig V, van Warmerdam LJ et al. Pharmacokinetics and metabolism of docetaxel administered as a 1-h intravenous infusion. Cancer Chemother Pharmacol 2000;45:213-218.
144. Myers BD, Ross J, Newton L et al. Cyclosporine-associated chronic nephropathy. N Engl J Med 1984;311:699-705.
145. Mayer U, Wagenaar E, Dorobek B et al. Full blockade of intestinal P-glycoprotein and extensive inhibition of bloodbrain barrier P-glycoprotein by oral treatment of mice with PSC833. J Clin Invest 1997;100:2430-2436.
146. Fassberg J, Stella VJ. A kinetic and mechanistic study of the hydrolysis of camptothecin and analogues. J Pharm Sci 1992;81:676-684.
147. Hsiang YH, Liu LF, Wall ME et al. DNA topoisomerase I-mediated cleavage and cytotoxicity of camptothecin analogs. Cancer Res 1989;49:4385-4389.
148. Zamboni WC, Bowman LC, Tan M et al. Interpatient variability in bioavailability of the intravenous formulation of topotecan given orally to children with recurrent solid tumors. Cancer Chemother Pharmacol 1999;43:454-460.
149. Gerrits CJH, Burris H, Schellens JH et al. Five days of oral topotecan, a phase I and pharmacologic study in adult patients with solid tumors. Eur J Cancer 1998;34:1030-1035.
150. Herben VMM, Ten Bokkel Huinink WW, Beijnen JH. Clinical pharmacokinetics of topotecan. Clin Pharmacokinet 1996;31:85-102.
151. Hendricks CB, Rowinsky EK, Grochow LB et al. Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue. Cancer Res 1992;52:2268-2278.
152. Ferry D, Moore M, Bartlett NL et al. Phase I and pharmacokinetic study targeting a 500 ng/ml plasma concentration of the potent multidrug resistance (MDR) modulator GF120918 with doxorubicin in patients with advanced solid tumors. Proc Am Soc Clin Oncol 1998;17:240.
153. Kruijtzer CMF, Beijnen JH, Rosing H et al. Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. J Clin Oncol 2002;20:2943-2950.
154. Vanhoefer U, Harstrick A, Achterrath W et al. Irinotecan in the treatment of colorectal cancer: Clinical overview. J Clin Oncol 2001;19:1501-1518.
155. Mathijssen RH, van Alphen RJ, Verweij J et al, Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 2001;7:2182-2194.
156. Kehrer DFS, Mathijssen RH, Verweij J et al. Modulation of irinotecan metabolism by ketoconazole. J Clin Oncol 2002;14:3122-3129.
157. Ratain MJ, Goh BC, Iyer L et al. A phase I study of irinotecan (CPT-11) with pharmacokinetic modulation by cyclosporin A (CsA) and phenobarbital (PB). Proc Am Soc Clin Oncol 1999;18:202a.
158. Mathijssen RHJ, Verweij J, de Bruijn P et al. Modulation of irinotecan (CPT-11) metabolism by St. John's wort in cancer patients. Proc Am Assoc Cancer Res 2002;43:2443a.
159. Carpenter CCJ, Cooper DA, Fischl MA et al. Antiretroviral therapy in adults. Updated recommendations of the international AIDS Society-USA Panel. JAMA 2000;283:381-390.
160. Eagling VA, Back DJ, Barry MG. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors ritonavir, saquinavir and indinavir. Br J Clin Pharmacol 1997;44:190-194.
161. Kempf DJ, Marsh KC, Kumar G et al. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob Agents Chemother 1997;41:654-660.
162. + T-cell counts in HIV infected patients. Ann Intern Med 1996;124:1039-1050.
163. Van Heeswijk RPG, Veldkamp AI, Mulder JW et al. Combination of protease inhibitors for the treatment of HIV-1-infected patients: A review of pharmacokinetics and clinical experience. Antiviral Ther 2001;6:201-229.
164. Koudriakova T, Iatsimirskaia E, Utkin I et al. Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: Mechanism-based inactivation of cytochrome P4503A by ritonavir. Drug Metabol Dispos 1998;26:552-561.
165. Kim AE, Dintaman JM, Waddell DS et al. Saquinavir, an HIV protease inhibitor is transported by P-glycoprotein. J Pharmacol Exp Ther 1998;286:1439-1445.
166. Lee CG, Gottesman MM, Cardarelli CO et al. HIV-1 protease inhibitors are substrates for the MDR1 multi drug transporter. Biochemistry 1998;37:3594-3601.
167. Alsenz J, Steffen H, Alex R. Active apical secretory efflux of the HIV protease inhibitors saquinavir and ritonavir in Caco-2 cell monolayers. Pharm Res 1998;15:423-428.
168. Hsu A, Granneman GR, Cao G et al. Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir. Clin Pharmacol Ther 1998;63:453-464.
169. Huisman MT, Smit JW, Wiltshire HR et al. P-glycoprotein limits oral bioavailability, brain and fetal penetration of saquinavir even with high-dose ritonavir. Mol Pharmacol 2001;59:806-813.
170. Huisman MT, Smit JW, Schinkel AH. Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors. AIDS 2000;14:237-242.
171. Kim RB, Fromm MF, Wandel C et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 1998;101:289-294.
172. Washington CB, Man MC, Wiltshire HR et al. The disposition of saquinavir in normal and P-glycoprotein deficient mice and cultured cells. Drug Metab Dispos 2000;28:1058-1062.